The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treat-to-Target Decisions and Dilemmas

Treat-to-Target Decisions and Dilemmas

July 12, 2011 • By David S. Pisetsky, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
David S. Pisetsky, MD, PhD

Reflecting on recent progress in the treatment of inflammatory arthritis, I am especially gratified by the concept of treat to target (T2T). T2T places our specialty smack in the mainstream of modern medicine. After all, much of internal medicine is based on T2T, whether the target is blood pressure, glycosylated hemoglobin (hemoglobin A1C) levels, or the international normalized ratio (INR). As a scientist, I like numbers, and I welcome them to our specialty. The more the better. Interestingly, some important clinical measures, such as the pulse rate or respiratory rate, have never been established as therapeutic targets because the range is large, and circumstances dictate where in the range the sweet spot lies. Of course, age is never explicitly a target for efforts at prevention or treatment—beyond it reaching a number as large as possible—but we hope it is at least three score and ten.

You Might Also Like
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Treat Rheumatoid Arthritis to Target
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
Explore This Issue
July 2011
Also By This Author
  • The Saddest Disease to Prevent

As those of you who are regular readers of The Rheumatologist (TR) know, T2T has long been a theme of our publication, and we have been pleased to publish articles on the history of the investigators who established the metrics that are currently the foundation of T2T. Thus, TR has recounted the seminal contributions of investigators such as the late John Sharp, Piet van Riel, Josef Smolen, Jim Fries, and Ted Pincus, among others. Without the pioneering work of these inspired individuals, rheumatology would not have targets at which to aim. In chronicling the story of outcome measures, we have not forgotten our lab-based colleagues. We already have started a series on outstanding scientists like Eng Tan, who founded modern serology and made testing of antinuclear antibodies an essential part of rheumatologic evaluation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Treat to target efforts could lead to better outcomes in the future.
Treat to target efforts could lead to better outcomes in the future.

For many years, I have been an enthusiast of the Disease Activity Score (DAS) and use it regularly when I see patients and teach house officers and fellows, constantly Googling “DAS calculator,” only to find a site established by a company with a biologic in its portfolio. The product was not a big seller, but the site remains available and is quite nifty. I like to punch in the numbers from my exam and see how close to target we currently are.

DAS Versus Patient-Reported Symptoms

Recently, along with a resident, I saw a patient whose DAS left me baffled. As is the practice in our teaching clinic, the house officer sees the patient first and presents the case to me for preliminary discussion. We then see the patient together, and I do my own history and physical exam. The resident that day was a bright young man, aspiring to a career peering though a colonoscope at colonic mucosa although, to his credit, he was interested in learning more rheumatology because of the association of inflammatory bowel disease with arthritis and the frequent use of tumor necrosis factor blockers for patients with active Crohn’s disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Education & Training, Rheuminations Tagged With: Diagnosis, patient care, rheumatologist, Treat-to-TargetIssue: July 2011

You Might Also Like:
  • More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations
  • Treat Rheumatoid Arthritis to Target
  • Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.